Stephens analyst Scott Fidel lowered the firm’s price target on Centene to $85 from $87 and keeps an Overweight rating on the shares. The firm’s prior view that Centene’s assumptions on Medicaid redeterminations are “meaningfully conservative” when compared to peers for 2023-2024 “remains fully intact” coming out of the Q2 report, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNC: